Full Text View
Tabular View
No Study Results Posted
Related Studies
5-Azacytidine Prior to Allogeneic Stem Cell Transplant in High Risk Myelodysplastic Syndrome
This study is ongoing, but not recruiting participants.
Study NCT00721214   Information provided by Virginia Commonwealth University

First Received on July 22, 2008.   Last Updated on April 23, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Myelodysplastic Syndrome
Additional conditions recognized in this trial
Myelodysplastic Syndromes
Preleukemia
More general conditions related to this trial
Bone Marrow Diseases
Hematologic Diseases
Neoplasms
Precancerous Conditions
Interventions listed in this trial
5-azacytidine
Additional drug interventions recognized in this trial
Azacitidine
More general drug interventions related to this trial
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Virginia Commonwealth University
Celgene Corporation


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services